Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Baxter International Inc.

Baxter Healthcare Sa

Baxter Vaccine Ag

Ology Bioservices Inc.

Nanotherapeutics, Inc.

Falko-Guenter Falkner

Friedrich Dorner

Uwe Schlokat

Johann J Eibl

Hans-Peter Schwarz

Bernhard Fischer

Peter Turecek

Manfred Reiter

Wolfgang Mundt

Artur Mitterer

Michele Himmelspach

Renate Den-Bouwmeester

Georg Holzer

Friedrich Scheiflinger

Randolf Kerschbaumer

Michael Pfleiderer

Sogue Coulibaly

Josef Mayrhofer

Johann Kohl

Thomas Haemmerle

Hartmut Ehrlich

Noel Barrett

Otfried Kistner

Christa Tauer

Manfred Oberreither

Sabine E Herlitschka

Hartmut Erlich

The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.

Production of viral vaccine

The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.

Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods

A liquid or liquid-frozen composition comprising: a modified vaccinia Ankara (MVA) virus or variant or derivative thereof and mannitol, wherein mannitol is the sole stabilization agent of the composition. The mannitol may provide a stabilizing effect at 0 to +10&#xb0; C. or in a liquid-frozen composition, for example between &#x2212;10&#xb0; C. and &#x2212;30&#xb0; C. or between &#x2212;20&#xb0; C. and &#x2212;23.5&#xb0; C. The MVA may be used as a vaccine or for use in gene therapy, virotherapy, immunotherapy, or cancer therapy in a mammal, preferably a human.

Vaccine formulations and uses thereof

An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.

Factor IX/factor IXa activating antibodies and antibody derivatives

Nucleic acids encoding factor X&#x394; analogues having a deletion of amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg 179 are provided.

Nucleic acids encoding factor X deletion mutants and analogues thereof

Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.

Factor X deletion mutants and analogues thereof

A chimeric poxvirus is disclosed, which comprises the sequences of the vector component of a retroviral vector particle and optionally the packaging component of a defective retroviral particle. The chimeric poxvirus according to the invention particularly can be used for applications in gene therapy or tumor therapy.

Chimeric poxvirus comprising sequences of a retroviral vector component

Fusion proteins of an optionally C-terminally deleted furin derivative, or of a derivative of a furin analogue, and a heterologous sequence, methods of preparing the same and methods of recovering proproteins from proteins by using the proproteins according to the invention are described.

Fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterologous sequence

The invention describes an expression plasmid containing a dicistronic transcription/translation unit, which unit comprises a sequence for a foreign protein and a sequence for a fusion protein, the fusion protein containing at least one selection marker and at least one amplification marker. Further described is a method of producing foreign proteins by using the plasmids according to the invention, as well as cell lines transformed with the plasmid according to the invention.

Expression plasmid, a fusion protein, a transfected eukaryotic cell

The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt. The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active. Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.

Method for isolation of highly pure von willebrand factor

The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt. The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active. Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity

Method for isolation of highly pure von Willebrand Factor

A method of quantitating genomic DNA in a sample is provided. The method comprises the steps of adding to the sample a given amount of at least one nucleic acid as an internal standard, wherein the standard nucleic acid differs from the genomic DNA to be quantified in at least one detectable characteristic; amplifying the genomic DNA and the internal standard nucleic acid by means of a nucleic acid amplification process employing primers complementary to repetitive genomic sequences; determining as a first amount the amount of amplified genomic DNA, and determining as a second amount the amount of amplified standard nucleic acid; and determining from the first and second amounts, as a third amount, the amount of genomic DNA originally contained in the sample. Kits for performing the method and products substantially free of foreign DNA as determined by the method also are provided.

Growing community of inventors

Orth/Donau, Austria

Falko-Guenter Falkner